Cycled Phototherapy

Description

Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (\< 750 g BW or \<27 weeks GA).

Conditions

Hyper Bilirubinemia, Premature Infant

Study Overview

Study Details

Study overview

Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (\< 750 g BW or \<27 weeks GA).

Cycled Phototherapy: A Safer Effective Method to Control the Serum Bilirubin Of Extremely Premature Infants?

Cycled Phototherapy

Condition
Hyper Bilirubinemia
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233

Palo Alto

Stanford University, Palo Alto, California, United States, 94304

San Diego

Sharp Mary Birch Hospital for Women & Newborns, San Diego, California, United States, 92123

Atlanta

Emory University, Atlanta, Georgia, United States, 30303

Chicago

Northwestern Lurie Children's Hospital of Chicago, Chicago, Illinois, United States, 60611

Iowa City

University of Iowa, Iowa City, Iowa, United States, 52242

Jackson

University of Mississippi Medical Center - Children's of Mississippi, Jackson, Mississippi, United States, 39216

Albuquerque

University of New Mexico, Albuquerque, New Mexico, United States, 87131

Rochester

University of Rochester, Rochester, New York, United States, 14642

Durham

RTI International, Durham, North Carolina, United States, 27705

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Infants is inborn
  • 2. Infant is ≤ 750 grams at birth and/or \< 27 weeks gestation at birth by best OB estimate
  • 3. Infant is 12-36 hours of age.
  • 1. Unable to enroll infant by 36 hours of age
  • 2. Previous phototherapy
  • 3. Known hemolytic disease
  • 4. TSB reported as \>6.0 mg/dL before 12 hours age
  • 5. Major anomaly
  • 6. Overt nonbacterial infection
  • 7. Infant is likely to expire soon: Limiting or withdrawal of intensive care is being recommended to the parents, the parents are requesting withdrawal of care, or the pH is \< 6.80 or persistent bradycardia with hypoxemia for \>2h.

Ages Eligible for Study

22 Weeks to 27 Weeks

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NICHD Neonatal Research Network,

Jon Tyson, MD, PRINCIPAL_INVESTIGATOR, The University of Texas Health Science Center, Houston

Study Record Dates

2025-07